Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
Clinical trial supply company strengthens its presence in the European Union
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
He will continue to lead business in LATAM and Asia regions in this new role
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
Key takeaways of Q3FY22 quarter & conference call highlights
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
